Biomarkers in lung cancer screening: the importance of study design
Eur Respir J
2021 Jan 14;57(1):2004367.
Print 2021 Jan.
David R Baldwin
Matthew E Callister
Philip A Crosbie
Emma L O'Dowd
Robert C Rintoul
Hilary A Robbins
Robert J C Steele
Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK firstname.lastname@example.org.
University of Nottingham, Nottingham, UK.
Leeds Teaching Hospitals, Leeds, UK.
University of Leeds, St James's University Hospital, Leeds, UK.
Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
Manchester Thoracic Oncology Centre, North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK.
Dept of Oncology, University of Cambridge, Cambridge, UK.
Dept of Thoracic Oncology, Royal Papworth Hospital, Cambridge, UK.
Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
UK National Screening Committee, Dept of Surgery, Ninewells Hospital, University of Dundee, Dundee, UK.
No abstract available
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Early Detection of Cancer*
Lung Neoplasms* / diagnosis
R03 CA245979/CA/NCI NIH HHS/United States
U19 CA203654/CA/NCI NIH HHS/United States
DH_/Department of Health/United Kingdom
CRUK_/Cancer Research UK/United Kingdom